Centessa Pharmaceuticals plc (Centessa), formerly Centessa Pharmaceuticals Limited, is a pharmaceutical company. The Company’s asset-centric programs range from discovery-stage to late-stage development and include diverse therapeutic areas such as oncology, hematology, immunology/inflammation, neuroscience, hepatology, pulmonology and nephrology. Its portfolio consists of approximately 16 conviction programs, including four programs evaluated in clinical trials and 12 additional preclinical programs. Centessa’s clinical stage product candidates include Lixivaptan, SerpinPC, Imgatuzumab and ZF874. The Company’s preclinical assets include ZF887, MGX292, CBS001, CBS004, LB1, LB2, Oral OX2R Agonist, Intranasal OX2R Agonist, Dual STAT3/5 Degrader, EGFR Ex20 Inhibitor, EGFR-C797S Inhibitor and EGFR Inhibitors. The Company’s subsidiaries include ApcinteX, Capella BioScience, Janpix, LockBody, Morphogen-IX, Orexia Therapeutics, Palladio Biosciences, PearlRiver Bio, PegaOne and Z Factor.